Related Experiment Video
Updated: Nov 21, 2025
09:36
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
3.0K
Complement Inhibition in Severe COVID-19 Acute Respiratory Distress Syndrome
Sharmila Raghunandan1,2, Cassandra D Josephson2,3, Hans Verkerke3
1Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.
Frontiers in Pediatrics
|January 15, 2021
Summary
Most children with COVID-19 experience mild illness, but severe cases can cause acute respiratory distress syndrome (ARDS). Complement-mediated lung injury may play a role, as suggested by a case treated with convalescent plasma and eculizumab.
Area of Science:
- Pediatric critical care medicine
- Immunology
- Infectious diseases
Background:
- COVID-19 in children often presents as mild or asymptomatic illness.
- Critically ill children with COVID-19 may develop acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI).
- Lung function deterioration in COVID-19 is associated with microangiopathic and immune-mediated processes, potentially involving complement activation.
Observation:
- The role of complement-mediated acute lung injury is supported by animal models, human autopsy data, and therapeutic responses.
- A case of a child with severe COVID-19 treated with convalescent plasma and eculizumab is presented.
- Detailed evaluation of inflammatory pathways in this case is provided.
Findings:
- Complement inhibition may be a therapeutic target for severe COVID-19 ARDS.
- Understanding inflammatory pathways is crucial for managing critical illness in children.
- Convalescent plasma and eculizumab were used in a pediatric case of severe COVID-19.
Implications:
- This case highlights the potential role of complement in pediatric COVID-19 lung injury.
- Further research into complement-targeted therapies for severe COVID-19 in children is warranted.
- Insights into inflammatory pathways can inform treatment strategies for critical COVID-19.
Keywords:
COVID - 19SARS-CoV-2acute respiratory distress syndrome (ARDS)childrencomplementeculizumabpediatricMore Related Videos
Related Concept Videos
01:27Complement System
6.7K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
6.7K
01:21Acute Respiratory Failure-II
756
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
756
01:29Acute Respiratory Failure-V
298
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
298
01:30Acute Respiratory Failure-III
518
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
518
01:21Acute Respiratory Failure-I
569
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
569
01:23Acute Respiratory Failure-IV
361
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
361